Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
The safety profile of sibeprenlimab was favorable and consistent with previously reported data
Immunoglobulin A nephropathy is a progressive, immune-mediated, chronic kidney disease that can lead to end-stage kidney disease (ESKD) over the lifetime of most patients under current optimized standard care
Sibeprenlimab filed its Biologics License Application (BLA) and received Priority Review designation from the U.S. Food and Drug Administration (FDA) with a target action date of November 28th, 2025
PRINCETON, N.J. & TOKYO, June 06, 2025--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group.1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo.
Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals2.
Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home.
"We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials," said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. "Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease."
The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN1.
"The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology," said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. "The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN."
About the VISIONARY Study
The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months1.
About Sibeprenlimab
Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss.
About IgAN and APRIL
IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients9,10,11.
IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5.
APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys5.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024.
All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at https://www.otsuka.co.jp/en/.
About Visterra
Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit www.visterrainc.com.
References
Otsuka Pharmaceutical Development & Commercialization, Inc.Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN). Clinicaltrials.gov. https://www.nejm.org/doi/full/10.1056/NEJMoa2305635
Thompson A, Carroll K, Inker LA, et al. Proteinuria Reduction as a Surrogate End Pointin Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469-481.doi:10.2215/CJN.08600718
Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022;7(5):993-1003.
Chang S, Li XK. The Role of Immune Modulation in Pathogenesis of IgA Nephropathy (nih.gov)
Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and April in IGA nephropathy: Pathogenic mechanisms and targeted therapies. Frontiers in nephrology. February 1, 2024.
Mathur M, Barratt J, Chacko B, et al. A Phase 2 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy Patients. NEJM. 2023 https://www.nejm.org/doi/full/10.1056/NEJMoa2305635
Gharavi, Ali G, et al. "Aberrant Iga1 Glycosylation Is Inherited in Familial and Sporadic IGA Nephropathy." Journal of the American Society of Nephrology : JASN, U.S. National Library of Medicine, May 2008, pmc.ncbi.nlm.nih.gov/articles/PMC2386728
Kant, Sam, et al. "Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review - American Journal of Kidney Diseases." American Journal of Kidney Diseases, Apr. 2022, www.ajkd.org/article/S0272-6386(21)00835-0/fulltext.
Pitcher, D. Braddon, et. al Long-term outcomes in IGA nephropathy. Clinical journal of the American Society of Nephrology : CJASN. https://pubmed.ncbi.nlm.nih.gov/37055195/.
Lai K. Iga nephropathy. Nature reviews. Disease primers. 2016
Cheung, Chee Kay & Boyd, JKF & Feehally, J.. (2012). Evaluation and management of IgA nephropathy. Clinical Medicine. 12. s27-s30. 10.7861/clinmedicine.12-6-s27.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250606873555/en/
Contacts
Contacts for Media
Otsuka in the U.S.
Robert MurphyCorporate CommunicationsOtsuka America Pharmaceutical, Inc.robert.murphy@otsuka-us.com
+1 609 249 7262
Otsuka in Japan
Jeffrey GilbertLeader, Pharmaceutical PROtsuka Pharmaceutical Co., Ltd.gilbert.jeffrey.a@otsuka.jp
+81 3 6361 7379
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Senate Democrat rips Costco for ‘refusing to sell' abortion pills
Sen. Patty Murray (D-Wash.) hammered Costco on Friday for appeasing 'far-right extremists,' after the retailer said earlier this week that its pharmacies would not dispense the abortion medication mifepristone. 'I am deeply alarmed by news reports that Costco is refusing to sell safe, effective, and legal medication for no other reason than to appease the politics of anti-abortion fanatics,' Murray said in a statement following the news. 'I refuse to stand by and allow far-right extremists to bully major corporations and dictate what medicine women can or cannot get access to.' 'Where it is legal, retailers and major pharmacies must absolutely make medication abortion available to the women who need it,' the Washington Democrat added. Costco, in its Thursday announcement, explained that the decision came from a 'lack of demand.' 'Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,' the company said, according to Reuters. The decision comes after CVS and Walgreens announced last year that they received certification to provide the drug in states where abortion remains legal. Murray pressed Costco to rescind its decision, warning that limiting access to mifepristone, one of two drugs used in medication abortion, is harmful to women's health. 'Mifepristone is safe and effective—we cannot live in a world where the availability of women's health care whipsaws back and forth based on the whims of extremists who want to deny women access to basic health care,' she wrote Friday. 'I am demanding that Costco immediately reverse course—follow the science and the facts, not the demands of far-right anti-abortion extremists.' The Supreme Court in a decision last year ruled unanimously that a group of anti-abortion doctors did not have the legal basis to challenge access to the pill. Despite the ruling, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary are weighing a review of the abortion pill. Murray questioned Makary during his Senate confirmation hearing on the proposal, as well as President Trump's moves to gut staff at the FDA.
Wall Street Journal
7 hours ago
- Wall Street Journal
What You Need to Know About Kratom
Millions of Americans take the herbal supplement kratom for everything from energy to pain relief to quitting opioids. You can find kratom capsules, powder, drinks and shots in health food stores, gas stations and smoke shops. But the Food and Drug Administration is pushing to effectively ban a kratom derivative known as 7-OH, citing its potential for abuse. Some doctors and substance-abuse counselors warn that there are signs the plant itself is potentially addictive. Users contend it confers pain and mood-related benefits and provides an alternative to opioids.
Forbes
8 hours ago
- Forbes
You May Now Give Yourself A Flu Vaccine At Home With FluMist Home
These days, there are more things that you can do at home by yourself that you couldn't do before such as sit in a business meeting without wearing any pants. Well, here's another thing that previously wasn't possible at home but now is: vaccinate yourself against the flu. Yep, if you are in one of the 34 eligible states in the U.S., you can now get the FluMist Home vaccine from AstraZeneca delivered to right to your home. And in case you missed what FluMist is, it's a nasal spray vaccine. So rather than sticking yourself with a needle, you can simply squirt the vaccine up your nose. FluMist Home Is The Home Version Of FluMist Vaccine The vaccine itself isn't new. The FluMist nasal spray vaccine received U.S. Food and Drug Administration approval back in 2003 to be used for those from five to 49 years of age. The FDA added kids from two through five years of age to this approval in 2007. But until last year, like all other flu vaccines, you had to get some kind of qualified healthcare worker to give you the vaccine. That all changed in September 2024 when the FDA approved FluMist to be the first self-administer-able flu vaccine out there. Not coincidentally, it's also the only nasal spray flu vaccine out there. It's probably a whole lot easier and safer for folks to squirt something up their noses rather than stick their arms with needles. Not surprisingly, AstraZeneca wasn't ready to go with the home version of FluMist, known as FluMist Home, last flu season, which was a particularly nasty one, as I covered in Forbes tat the time. But the company is ready for this upcoming flu season. Starting this fall, if you are an adult under 50 or a parent of a child who's older than two you can order the vaccine via an online platform. Now you will have to complete a medical screening questionnaire that will be reviewed by a licensed healthcare professional before the vaccines gets prescribed to you or your tykes. Most types of commercial insurance should cover this vaccine. But you may have to fork out $8.99 for shipping and handling. Now, if you are an adult 50 years or older or a kid from six months up to two years of age and saying WTF, as in 'what the FluMist,' for me, you aren't eligible for this vaccine. That's because the vaccine uses live (but weakened) versions of the flu virus, which is different from the other flu vaccines that use dead or inactivated versions of the flu virus. The live, weakened versions of the flu virus may generate a stronger immune response and thus stronger protection than the dead versions. However, if you've got a weaker immune systems such as when you get older than 50 or are younger than two years of age, you want to be careful about getting a live virus, even if it is weakened, injected into you. FluMist Home Could Help Increase Flu Vaccination Rates The flu vaccine typically offers anywhere from 30% to 60% protection against the flu, depending on how well the flu strains in the flu vaccine match the circulating strains that year. Since it takes about six months to produce the flu vaccine, the selection of the strains for the vaccine need to occur well in advance of the flu season. That's why sometimes it's a good match, sometimes things are way off and often it's somewhere in between. As with many other vaccines against infectious diseases, how well you are protected against the flu does depend on how many other people around you got vaccinated as well. Last flu season, an estimated 46.7% of adults and 49.2% of children got vaccinated against the flu. That's compared to 49.2% and 53.4% for the flu season prior in 2023-2024, according the Centers for Disease Control and Prevention data. These close-to-but-not-quite-half have been rather typical each flu season recently, as I have written in Forbes previously. Those numbers ain't great. You may have heard of the concept of herd immunity, which I have written about before in Forbes. While the flu vaccine will help protect the individuals who got it, ideally you want the vaccination coverage to be significantly higher than the herd immunity threshold for flu, which is around 50%. When the vaccination coverage is well above the herd immunity threshold, the virus begins to run out of susceptible people to infect, which in turn slows the spread of the flu virus in the population. It's not completely clear why over the half the U.S. population did not get the flu vaccine last flu season. For some, it might have been a matter of convenience. They may have not gotten vaccinated simply because they didn't find the time to take time off from work to go to a clinic or pharmacy. For such folks, having something like FluMist Home available may increase their chances of getting vaccinated.
